AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

  • New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
  • Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
  • Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

/by

FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases

  • Erelzi is approved for all indications included in the reference product’s label
     
  • Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
     
  • Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

/by

FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases

  • Erelzi is approved for all indications included in the reference product’s label
     
  • Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
     
  • Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

/by

Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress

  • First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
  • Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
  • Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.

Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …

/by

Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress

  • First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
  • Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
  • Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.

Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …

/by

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects

  • Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact
    • Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth
    • Cosentyx (USD 260 million) grew strongly driven by its three approved indications
  • Core[1] operating income declined (-4% cc) due to generic erosion and growth investments
    • Core M&S expenses up 0.8 percentage points (cc) to 24.6% of sales, mainly driven by Cosentyx, Entresto and Alcon …
/by

Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases

  • Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product
  • Committee’s recommendation based on totality of evidence from global development program showing biosimilar etanercept is highly similar to Enbrel®*

Holzkirchen, 13 July, 2016. Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept. The committee voted unanimously ( …

/by

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

  • The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12
  • As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate in psoriasis
  • Sandoz biosimilar etanercept has been accepted for review by the EMA* and FDA**

Holzkirchen, July 7, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which …

/by

Sandoz announces plans for five major global biosimilar launches by 2020

  • Progress on biosimilar pipeline paves way for five planned launches by 2020
  • Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on six
  • Investments of more than USD 1 billion in state of-the-art biomanufacturing facilities, backed by industry-leading capabilities as part of Novartis, positions Sandoz to deliver biosimilars at unprecedented scale

Holzkirchen, June 20, 2016 – Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and …

/by

New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

  • Sandoz’ biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.1

  • Sandoz’ biosimilar rituximab candidate shows PK bioequivalence and similar pharmacodynamics (PD), safety, efficacy and immunogenicity.2

  • Biosimilar etanercept candidate is under regulatory review by EMA* and FDA** and biosimilar rituximab candidate is undergoing EMA review.

Holzkirchen, June 9, 2016 – Sandoz, a …

/by